Stocks · News reference
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lucid Diagnostics Inc. has been named a 2026 Best Places to Work honoree by GenomeWeb, marking the company's second consecutive year receiving this recognition.
Lucid Diagnostics announced that its Chairman and CEO, Lishan Aklog, M.D., will participate in a panel discussion at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
Lucid Diagnostics has announced the publication of a significant real-world study involving 12,000 patients evaluating its EsoGuard esophageal DNA test.
Lucid Diagnostics announced it will host a conference call and webcast to provide a business update for the third quarter of 2026 on November 12, 2026.
Analyst Anthony Vendetti of Maxim Group LLC has reiterated a 'Buy' rating and a $2.00 price target for Lucid Diagnostics Inc. (LUCD).
With U.S. crude above $100 per barrel, investors are turning to smaller companies with emerging technologies. Kraig Biocraft Laboratories shipped its first commercial spider silk order, Hyperscale Data reaffirmed 2027 revenue guidance of $300-350 million, Lucid Diagnostics began receiving Medicare payments for its EsoGuard test, and 22nd Century Group reported 66% quarterly revenue growth with improving profitability metrics.